Current Developments in Pharmacogenomics of Multiple Sclerosis

Cellular and Molecular Neurobiology

Volumn 34, Issue 8, 2014, Pages 1081-1085

  Carlson, Rebecca J ^a   Doucette, J Ronald ^a,b,c   Nazarali, Adil J ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Saskatoon City Hospital   (Canada)

Author keywords

Genome wide association studies; Glatiramer acetate; Interferon ; Multiple sclerosis; Pharmacogenomics; SNPs

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON REGULATORY FACTOR 5; MERCAPTOPURINE; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB;

BIOAVAILABILITY; CENTRAL NERVOUS SYSTEM; GENETIC MARKER; GENETIC VARIABILITY; HEALTH PRACTITIONER; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHARMACOGENOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; TREATMENT RESPONSE; ANIMAL; GENETICS; PHARMACOGENETICS; RESEARCH; TRENDS;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; PHARMACOGENETICS; RESEARCH;

EID: 84912012860     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-014-0095-0     Document Type: Review

References (17)

1. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR (2009) Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 18(4):767–778
2. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL, Multiple Sclerosis Genetics Group (2003) HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. American Journal of Human Genetics 72(3):710–716
3. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D, Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR (2008) Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 65(3):337–344
4. Cénit MD, Blanco-Kelly F, de las Heras V, Bartolomé M, de la Concha EG, Urcelay E, Arroyo R, Martínez A (2009) Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 15(8):913–917
5. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X (2009) Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 66(8):972–978
6. Cotte S, von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK, Starck M, König N, Tellez N, Dörr J, Paul F, Zipp F, Lühder F, Koepsell H, Pannek H, Montalban X, Gold R, Chan A (2009) ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132(Pt 9):2517–2530
7. Dhib-Jalbut S, Valenzuela RM, Ito K, Kaufman M, Picone MA, Buyske S (2013) HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis. Mult Scler Relat Disord 2(4):340–348
8. Fusco C, Andreone V, Coppola G, Luongo V, Guerini F, Pace E, Florio C, Pirozzi G, Lanzillo R, Ferrante P, Vivo P, Mini M, Macrì M, Orefice G, Lombardi ML (2001) HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing–remitting multiple sclerosis. Neurology 57:1976–1979
9. Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, Weiner HL, Hafler DA, De Jager PL (2011) Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol 233(1–2):168–174
10. Grossman I, Avidan N, Singer C, Goldstaub D, Hayardeny L, Eyal E, Ben-Asher E, Paperna T, Pe’er I, Lancet D, Beckmann JS, Miller A (2007) Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genom 17(8):657–666
11. Hoffman-La Roche Ltd. (2013) Product monograph: Herceptin.http://www.rochecanada.com/fmfiles/re7234008/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Herceptin/Herceptin_PM_E.pdf
12. Kulakova OG, Tsareva EY, Lvovs D, Favarov AV, Boyko AN, Favarova OO (2014) Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. Pharmacogenomics 15(5):679–685
13. Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, Comabella M, Montalban X (2006) Defining the response to interferon-β in relapsing–remitting multiple sclerosis patients. Ann Neurol 59:344–352
14. The National Collaborating Centre for Chronic Conditions (2004) Multiple sclerosis: National clinical guideline for diagnosis and management in primary and secondary care. http://www.ncbi.nlm.nih.gov/pubmed/21290636
15. Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV, Gusev EI, Vandenbroeck K, Favorova OO (2012) Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. Pharmacogenomics 13(1):43–53
16. Vandenbroeck K, Alloza I, Swaminathan B, Antigüedad A, Otaegui D, Olascoaga J, Barcina MG, de las Heras V, Bartolomé M, Fernández-Arquero M, Arroyo R, Alvarez-Lafuente R, Cénit MC, Urcelay E (2011) Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection. Genes Immun 12(1):40–45
17. Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der Pouw Kraan TC, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL (2011) Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of interferonβ therapy in multiple sclerosis. Genes Immun 12(6):466–472